FBRX · Forte Biosciences, Inc.
$50.73
+3.24 (+6.82%)
At close · Jul 21
Market Cap
$704.42M
Shares
13.89M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$36K
-99.8%
FY2019
Net Income
-$69.38M
-95.5%
FY2025
Operating Margin
-11288.89%
-11034.7pp
FY2019
Diluted EPS
-$4.71
+61.3%
FY2025
Operating Cash Flow
-$50.88M
-65.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | $36K | $18.04M | $41K | $49K | — | |
| — | $2.72M | $1.31M | $1.12M | $162K | — | — | — | — | — | — | — | |
| $65.43M | $57.65M | $20.71M | $21.86M | $5.59M | $13.85M | $10M | $45.3M | $51.08M | $29.11M | $27.22M | $19.17M | |
| $10.95M | $12.41M | $15.41M | $10.62M | $8.3M | $7.63M | $4.22M | $1.38M | $12.81M | $8.56M | $4.52M | $3.83M | |
| $3.5M | — | — | — | — | — | — | $900K | — | — | — | — | |
| $76.97M | $70.66M | $36.6M | $32.49M | $13.9M | $21.49M | $46.28M | $4.06M | $63.89M | $37.67M | $31.74M | $23.01M | |
| -$76.97M | -$70.66M | -$36.6M | -$32.49M | -$13.9M | -$21.49M | -$46.28M | -$4.06M | -$45.85M | -$37.63M | -$31.69M | -$22.95M | |
| — | — | — | — | — | — | — | -11288.89% | -254.23% | -91775.61% | -64673.47% | — | |
| $2.53M | $2.32M | $1.12M | -$114K | -$145K | -$222K | -$205K | -$5000 | — | -$1.3M | -$1.79M | -$102K | |
| — | -$68.34M | -$35.48M | -$31.48M | — | — | — | -$63.52M | -$47.26M | -$38.93M | -$33.48M | — | |
| — | $1.04M | $0 | — | — | — | — | $1000 | $1.7M | $1000 | $1000 | — | |
| -$75.86M | -$69.38M | -$35.48M | -$31.48M | -$13.88M | -$21.71M | -$46.49M | -$4.07M | -$48.96M | -$38.93M | -$33.48M | -$23.06M | |
| — | — | — | — | — | — | — | -11302.78% | -271.43% | -94948.78% | -68322.45% | — | |
| -$75.86M | -$69.38M | -$35.47M | -$31.47M | -$13.88M | — | — | -$63.48M | -$48.94M | -$38.96M | -$33.42M | -$23.11M | |
| USD/shares | — | -$4.71 | -$12.17 | -$24.92 | -$20.00 | -$38.75 | — | — | — | — | — | — |
| USD/shares | — | -$4.71 | -$12.17 | -$24.92 | -$20.00 | -$38.75 | — | — | — | — | — | — |
| shares | — | — | — | — | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 5866.5707 | 5818.752 |
| shares | — | — | — | — | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 5866.5707 | 5818.752 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×